Associations of maternal and fetal 25-hydroxyvitamin D levels with childhood eczema: The Generation R Study

Gazibara, Tatjana, Elbert, Niels J., den Dekker, Herman T., de Jongste, Johan C., Reiss, Irwin, McGrath, John J., Eyles, Darryl W., Burne, Thomas H., Tiemeier, Henning, Jaddoe, Vincent W. V., Pasmans, Suzanne G. M. A. and Duijts, Liesbeth (2016) Associations of maternal and fetal 25-hydroxyvitamin D levels with childhood eczema: The Generation R Study. Pediatric Allergy and Immunology, 27 3: 283-289. doi:10.1111/pai.12530


Author Gazibara, Tatjana
Elbert, Niels J.
den Dekker, Herman T.
de Jongste, Johan C.
Reiss, Irwin
McGrath, John J.
Eyles, Darryl W.
Burne, Thomas H.
Tiemeier, Henning
Jaddoe, Vincent W. V.
Pasmans, Suzanne G. M. A.
Duijts, Liesbeth
Title Associations of maternal and fetal 25-hydroxyvitamin D levels with childhood eczema: The Generation R Study
Journal name Pediatric Allergy and Immunology   Check publisher's open access policy
ISSN 0905-6157
1399-3038
Publication date 2016-05
Sub-type Article (original research)
DOI 10.1111/pai.12530
Open Access Status Not Open Access
Volume 27
Issue 3
Start page 283
End page 289
Total pages 7
Place of publication Chichester, West Sussex, United Kingdom
Publisher Wiley-Blackwell Publishing
Collection year 2017
Language eng
Formatted abstract
Background
Exposure to low levels of vitamin D in fetal life might affect the developing immune system, and subsequently the risk of childhood eczema. We examined whether 25-hydroxyvitamin D levels in mid-gestation and at birth were associated with the risk of eczema until the age of 4 years.

Methods
In a population-based prospective cohort study of 3019 mothers and their children, maternal blood samples in mid-gestation and umbilical cord blood samples at birth were used to determine 25-hydroxyvitamin D levels (severely deficient <25.0 nmol/l, deficient 25.0–49.9 nmol/l, sufficient 50.0–74.9 nmol/l, optimal ≥75.0 nmol/l). Eczema was prospectively assessed by annual questionnaires until the age of 4 years. Eczema patterns included never, early (age ≤1 year only), late (age >1 year only), and persistent eczema (age ≤ and >1 year). Data were assessed using the generalized estimating equations and multinomial regression models.

Results
Compared with the optimal 25-hydroxyvitamin D group, sufficient, deficient, and severely deficient groups of 25-hydroxyvitamin D level in mid-gestation were not associated with the risk of overall eczema (odds ratios [95% confidence interval]: 1.09 [0.82, 1.43], 1.04 [0.87, 1.25], and 0.94 [0.81, 1.10], p-values for trend >0.05), nor with eczema per year or eczema patterns in children up to the age of 4 years. Similarly, we observed no associations of 25-hydroxyvitamin D groups at birth with any eczema outcome.

Conclusion

Our results suggest that levels of 25-hydroxyvitamin D in mid-gestation and at birth are not associated with the risk of overall eczema, eczema per year, or eczema patterns among children until the age of 4 years.
Keyword 25-hydroxy vitamin D
Birth
Child
Eczema
Pregnancy
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: HERDC Pre-Audit
Queensland Brain Institute Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in Thomson Reuters Web of Science Article
Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Fri, 11 Mar 2016, 15:46:14 EST by Susan Day on behalf of Queensland Brain Institute